IMDX חוב כולל להון Insight Molecular

Insight Molecular Diagnostics (IMDX) efficiency is based on the accuracy of its oncology tests and their recognition by physicians for treatment selection. The business's stability is ensured by the humanitarian status of medicine and operations within safe Western countries. This chart for the company on GURU.Markets demonstrates the debt-to-equity ratio, which stands at 0.00. Simultaneously, the genetic panel developer is implementing energy-saving measures and strictly controlling bio-waste processing in accordance with ESG standards.

Insight Molecular Diagnostics maintains significant pricing power within the inelastic demand segment for tumor markers, enabling effective control over its total debt-to-equity ratio. This indicator is calculated by dividing total liabilities by net assets, determining the degree of financial leverage and the business's reliance on external borrowings to ensure the long-term sustainability of its capital structure.